1Pfaller MA,Diekema DJ.Rare and emerging opportunistic fungal pathogens:concern for resistance beyond Candida albicans and Aspergillus fumigatus.J Clin Microbiol,2004,42:4419.
2Hajjeh RA,AN Sofair,LH Harrison,et al.Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.J Clin Microbiol,2004,42:1519.
3Pfaller MA,Diekema DJ.Twelve years of fluconazole in clinical practice:global trends in species distribution and fluconazole susceptibility of bloodstream isolates of candida.Clin Microbiol Infect,2004,10:11.
4Hughes WT,Armstrong D,Bodey GP,et al.Guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis,2002,34:730.
5Dykewicz CA.Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.Clin Infect Dis 2001,33:139.
6Patricia M,Almudena B.Criteria used when initiating antifungal therapy against Candida spp.in the intensive care unit.Int J of Antimicro Agents,2000,15:83.
7Sharma A,Lokeshwar N.Febrile neutropenia in haematolngical malignancies.J Postgrad Med,2005,51:42.
8Kojima R,Tateishi U,Kami M,et al.:Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation.Biol.Blood Marrow Transplant,2005,11:506.
9Sobel JD,Lundstrom T.Management of candiduria.Curr Urol Rep,2001,2:321.
10Joseph S.Selection of patients for empirical antifungal therapy.Presented Focus on Fungal infections Ⅱ.Washington DC USA,2001,4:14.
